- Home
- KZIA
as 07-26-2024 4:00pm EST
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
| Founded: | 1994 | Country: | Australia |
| Employees: | N/A | City: | NEW SOUTH WALES 2113 |
| Market Cap: | 15.6M | IPO Year: | 1999 |
| Target Price: | $2.00 | AVG Volume (30 days): | 38.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.19 - $1.58 | Next Earning Date: | 09-03-2024 |
| Revenue: | $15,650 | Revenue Growth: | 1025.49% |
| Revenue Growth (this year): | 97726.09% | Revenue Growth (next year): | N/A |
Latest Kazia Therapeutics Limited News
KZIA Breaking Stock News: Dive into KZIA Ticker-Specific Updates for Smart Investing
Zacks
14 days ago
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
Clinical Trials Arena
16 days ago
Kazia Therapeutics stocks soar following Phase II/III win
MT Newswires
16 days ago
Kazia Therapeutics' Phase 2/3 Trial for Paxalisib in Glioblastoma Brain Cancer Shows Clinically Significant Improvement
PR Newswire
17 days ago
Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma
PR Newswire
a month ago
KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER
CNW Group
2 months ago
Lotto 6/49 - $64 million up for grabs in the next draw!
Simply Wall St.
2 months ago
Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
AFP
2 months ago
Seoul says it will resume loudspeaker propaganda against North
Compare KZIA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KZIA Kazia Therapeutics Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.